{"id":459,"date":"2023-01-09T10:41:00","date_gmt":"2023-01-09T18:41:00","guid":{"rendered":"https:\/\/www.adarx.com\/?p=459"},"modified":"2024-12-13T08:34:05","modified_gmt":"2024-12-13T16:34:05","slug":"adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer","status":"publish","type":"post","link":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\/","title":{"rendered":"ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">SAN DIEGO\u2013(BUSINESS WIRE)\u2013<a href=\"https:\/\/www.adarx.com\/dev\/\">ADARx Pharmaceuticals, Inc.<\/a>, a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Robert MacLeod, Ph.D. as Chief Scientific Officer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cI am delighted to welcome Robert to ADARx with his extensive experience in the oligonucleotide field,\u201d said Dr. Zhen Li, President, and Chief Executive officer of ADARx. \u201cAs ADARx continues to grow, Robert will help to drive the evolving research and development needs of our organization. Robert\u2019s experience in the discovery and development of RNA therapeutics across multiple therapeutic areas supports our goal of turning cutting-edge science into life-saving therapeutics.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dr. MacLeod joins ADARx as ADX-324 for the treatment of hereditary angioedema is currently enrolling healthy volunteers for its phase I clinical trial. ADARx has two additional drug candidates set to enter clinical trials in 2023 and an extensive pipeline to follow. Prior to ADARx, Dr. MacLeod served as the Chief Scientific Officer at Flamingo Therapeutics after holding several positions at Ionis Pharmaceuticals, most recently as Vice President and Franchise Head of Oncology. He has led the strategic and scientific efforts of several multidisciplinary drug discovery teams leading to the discovery and clinical development of 15 novel investigational therapeutics and over 100 high impact scientific publications and patents. Dr. MacLeod received his B.S. in Chemistry and Biochemistry from Concordia University in Montreal Canada, and his Ph.D. in Cancer Epigenetics from McGill University.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cIt\u2019s an exciting time in RNA therapeutics and I believe ADARx will be a leader in this space with its broad approach to discovering and developing novel therapies,\u201d said Dr. MacLeod. \u201cI look forward to contributing to the impressive advances in the ADARx platforms that have already generated its first clinical stage program and a deep discovery pipeline in the Company\u2019s still short history.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>About ADARx<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics. ADARx is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Contact&nbsp;<\/strong><strong>ADARx&nbsp;<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Roselle Corbaley<br>(877) 232-7974<br><a href=\"mailto:ir@adarx.com\">ir@adarx.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO\u2013(BUSINESS WIRE)\u2013ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Robert MacLeod, Ph.D. as Chief Scientific Officer. \u201cI am delighted to welcome Robert to ADARx with his extensive experience in the oligonucleotide field,\u201d said Dr. Zhen Li, President, and Chief [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4],"tags":[],"class_list":["post-459","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer - ADARx Pharmaceuticals<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer - ADARx Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO\u2013(BUSINESS WIRE)\u2013ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Robert MacLeod, Ph.D. as Chief Scientific Officer. \u201cI am delighted to welcome Robert to ADARx with his extensive experience in the oligonucleotide field,\u201d said Dr. Zhen Li, President, and Chief [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"ADARx Pharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-09T18:41:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-13T16:34:05+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#\\\/schema\\\/person\\\/31790f93b65593567a6726ca407a0031\"},\"headline\":\"ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer\",\"datePublished\":\"2023-01-09T18:41:00+00:00\",\"dateModified\":\"2024-12-13T16:34:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\\\/\"},\"wordCount\":398,\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\\\/\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\\\/\",\"name\":\"ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer - ADARx Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#website\"},\"datePublished\":\"2023-01-09T18:41:00+00:00\",\"dateModified\":\"2024-12-13T16:34:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#\\\/schema\\\/person\\\/31790f93b65593567a6726ca407a0031\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#website\",\"url\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/\",\"name\":\"ADARx Pharmaceuticals\",\"description\":\"Providing hope for patients with intractable disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.adarx.com\\\/dev\\\/#\\\/schema\\\/person\\\/31790f93b65593567a6726ca407a0031\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.adarx.com\\\/dev\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer - ADARx Pharmaceuticals","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer - ADARx Pharmaceuticals","og_description":"SAN DIEGO\u2013(BUSINESS WIRE)\u2013ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Robert MacLeod, Ph.D. as Chief Scientific Officer. \u201cI am delighted to welcome Robert to ADARx with his extensive experience in the oligonucleotide field,\u201d said Dr. Zhen Li, President, and Chief [&hellip;]","og_url":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\/","og_site_name":"ADARx Pharmaceuticals","article_published_time":"2023-01-09T18:41:00+00:00","article_modified_time":"2024-12-13T16:34:05+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\/#article","isPartOf":{"@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\/"},"author":{"name":"admin","@id":"https:\/\/www.adarx.com\/dev\/#\/schema\/person\/31790f93b65593567a6726ca407a0031"},"headline":"ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer","datePublished":"2023-01-09T18:41:00+00:00","dateModified":"2024-12-13T16:34:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\/"},"wordCount":398,"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\/","url":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\/","name":"ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer - ADARx Pharmaceuticals","isPartOf":{"@id":"https:\/\/www.adarx.com\/dev\/#website"},"datePublished":"2023-01-09T18:41:00+00:00","dateModified":"2024-12-13T16:34:05+00:00","author":{"@id":"https:\/\/www.adarx.com\/dev\/#\/schema\/person\/31790f93b65593567a6726ca407a0031"},"breadcrumb":{"@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.adarx.com\/dev\/adarx-pharmaceuticals-expands-leadership-team-appointing-robert-macleod-ph-d-as-chief-scientific-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.adarx.com\/dev\/"},{"@type":"ListItem","position":2,"name":"ADARx Pharmaceuticals Expands Leadership Team, Appointing Robert MacLeod, Ph.D. as Chief Scientific Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.adarx.com\/dev\/#website","url":"https:\/\/www.adarx.com\/dev\/","name":"ADARx Pharmaceuticals","description":"Providing hope for patients with intractable disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adarx.com\/dev\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.adarx.com\/dev\/#\/schema\/person\/31790f93b65593567a6726ca407a0031","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/82dca50dfde45fa56a258e833d248704e572b0696fdf3e8ee3811447b2faaf1c?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.adarx.com\/dev"]}]}},"_links":{"self":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/posts\/459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/comments?post=459"}],"version-history":[{"count":2,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/posts\/459\/revisions"}],"predecessor-version":[{"id":508,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/posts\/459\/revisions\/508"}],"wp:attachment":[{"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/media?parent=459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/categories?post=459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.adarx.com\/dev\/wp-json\/wp\/v2\/tags?post=459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}